NEK9

Across TCGA pan-cancer cohorts, NEK9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NEK9 data layer compared with 23 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher NEK9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NEK9 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

GBM, CCRCC, and LUAD are the cancer types where NEK9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.610	0.818	<.001	14	view →
CCRCC	DFS	Quartile	III,IV	0.883	0.459	.007	4	view →
LUAD	DFS	Quartile	II,III,IV	0.745	0.309	.047	2	view →
PDAC	OS	Median	II,III,IV	0.503	0.308	.047	1	view →
HNSC	DFS	Median	II,III,IV	0.567	0.741	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NEK9–GBM (DFS)

Open the GBM breakdown →